Logo image of CLYM

CLIMB BIO INC (CLYM) Stock Fundamental Analysis

NASDAQ:CLYM - Nasdaq - US28658R1068 - Common Stock - Currency: USD

1.47  0 (0%)

After market: 1.47 0 (0%)

Fundamental Rating

3

CLYM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CLYM as it has an excellent financial health rating, but there are worries on the profitability. CLYM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CLYM had negative earnings in the past year.
In the past year CLYM has reported a negative cash flow from operations.
In the past 5 years CLYM always reported negative net income.
In the past 5 years CLYM always reported negative operating cash flow.
CLYM Yearly Net Income VS EBIT VS OCF VS FCFCLYM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

CLYM has a better Return On Assets (-31.11%) than 65.27% of its industry peers.
CLYM's Return On Equity of -31.59% is fine compared to the rest of the industry. CLYM outperforms 76.79% of its industry peers.
Industry RankSector Rank
ROA -31.11%
ROE -31.59%
ROIC N/A
ROA(3y)-31.78%
ROA(5y)-44.63%
ROE(3y)-32.97%
ROE(5y)-48.21%
ROIC(3y)N/A
ROIC(5y)N/A
CLYM Yearly ROA, ROE, ROICCLYM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

CLYM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLYM Yearly Profit, Operating, Gross MarginsCLYM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, CLYM has more shares outstanding
CLYM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLYM Yearly Shares OutstandingCLYM Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
CLYM Yearly Total Debt VS Total AssetsCLYM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

CLYM has an Altman-Z score of 16.64. This indicates that CLYM is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 16.64, CLYM belongs to the best of the industry, outperforming 92.67% of the companies in the same industry.
CLYM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.64
ROIC/WACCN/A
WACCN/A
CLYM Yearly LT Debt VS Equity VS FCFCLYM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

CLYM has a Current Ratio of 57.73. This indicates that CLYM is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 57.73, CLYM belongs to the best of the industry, outperforming 99.30% of the companies in the same industry.
A Quick Ratio of 57.73 indicates that CLYM has no problem at all paying its short term obligations.
CLYM has a Quick ratio of 57.73. This is amongst the best in the industry. CLYM outperforms 99.30% of its industry peers.
Industry RankSector Rank
Current Ratio 57.73
Quick Ratio 57.73
CLYM Yearly Current Assets VS Current LiabilitesCLYM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M

More info and screens

1

3. Growth

3.1 Past

CLYM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.57%.
EPS 1Y (TTM)-45.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CLYM will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.83% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-20.77%
EPS Next 2Y22.16%
EPS Next 3Y10.83%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLYM Yearly Revenue VS EstimatesCLYM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026
CLYM Yearly EPS VS EstimatesCLYM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLYM. In the last year negative earnings were reported.
Also next year CLYM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLYM Price Earnings VS Forward Price EarningsCLYM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLYM Per share dataCLYM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.16%
EPS Next 3Y10.83%

More info and screens

0

5. Dividend

5.1 Amount

CLYM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLIMB BIO INC

NASDAQ:CLYM (3/7/2025, 8:15:15 PM)

After market: 1.47 0 (0%)

1.47

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners86.56%
Inst Owner ChangeN/A
Ins Owners0.75%
Ins Owner Change32.62%
Market Cap98.81M
Analysts85.71
Price Target10.2 (593.88%)
Short Float %3.15%
Short Ratio3.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.45
P/tB 0.45
EV/EBITDA N/A
EPS(TTM)-2.13
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS3.25
TBVpS3.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.11%
ROE -31.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.78%
ROA(5y)-44.63%
ROE(3y)-32.97%
ROE(5y)-48.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 57.73
Quick Ratio 57.73
Altman-Z 16.64
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-45.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.48%
EPS Next Y-20.77%
EPS Next 2Y22.16%
EPS Next 3Y10.83%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y57.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.14%
OCF growth 3YN/A
OCF growth 5YN/A